By clearly defining the impact of EAE_postIF on neuroinflammation and demyelination, and identifying the PERK–autophagy axis as a key mediator, this work establishes a proof-of-concept for a novel therapeutic avenue in MS. This evidence concerns the gene EIF2AK3 and myeloid sarcoma.